NS7, in this particular case (where a new drug has not yet received gov't coverage) I think it makes a lot of sense. Otherwise they would be wasting their efforts as most people would balk at the high price. Better to really push it when you know that at least cost will not be an impediment.
NS It’s normal to pause all dinner/speaker presentations during December because people are too busy and away on holidays. As for PI2, they didn’t have the resources to have enough recruiting sites to be able to be selective for the higher risk Pts. They should have had an interim analysis to discover they weren’t going to be stat sig and expand or extend the trial (larger number or become more selective). The data still implies to me that V works (roughly 22% reduction in hospitalizations) and the fact that Amarin has decided to just walk away from further investigation is troubling. Here is a great example of how Pfizer would have just doubled the trial overnight and assured stat sig data (stay calm couldbebetter). Pfizer would also have the resources to run a large long COVID trial for all the CVD post COVID complications. Oh, what could have been.
Market Data 
Markets 
AI
